Compare Abeona Therapeutics Inc (ABEO) vs Workiva Inc (WK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Workiva Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Workiva Inc trades at $52.43 (market cap $2.97B). The key difference: Workiva Inc is far larger — about 8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | WK | |
|---|---|---|
Market Cap | $373.32M | $2.97B |
Sector | Health | Technology |
52-Week High | $7.23 | $93.31 |
52-Week Low | $4.17 | $44.31 |
Enterprise Value | $228.22M | $2.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Workiva (WK) trades at $51.54, down 0.75% on the day, with a bullish technical signal from moving averages and strong analyst consensus. The company reported Q1 2026 EPS of $0.77, beating estimates, and shows improving revenue trends. Cash flow from operations grew to $140.07M in 2025, with net income turning positive in 2026 projections. Recent news highlights AI adoption in finance and upcoming Q2 2026 earnings.
Outlook remains positive with a consensus price target of $71.00, implying 38% upside, supported by 16 buy ratings. Risks include high valuation multiples (P/E 214.75) and reliance on sustained earnings growth. The stock presents a growth opportunity if execution continues, but volatility near resistance at $52 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
